vorinostat
Sign in to saveAlso known as SAHA, suberoylanilide hydroxamic acid, SHH, octanedioic acid hydroxyamide phenylamide, Suberoylanilide hydroxamic acid, Octanedioic acid hydroxyamide phenylamide, suberanilohydroxamic acid
Vorinostat (rINN), also known as suberoylanilide hydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA), is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities.
Research
3,228 papers- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.The Lancet. Oncology · 2018
- Vorinostat as potential antiparasitic drug.European review for medical and pharmacological sciences · 2020
- Repurposing Vorinostat for the Treatment of Disorders Affecting Brain.Neuromolecular medicine · 2021
- Vorinostat in autophagic cell death: A critical insight into autophagy-mediated, -associated and -dependent cell death for cancer prevention.Drug discovery today · 2022
- Vorinostat for treatment-refractory bullous pemphigoid.Journal of the European Academy of Dermatology and Venereology : JEADV · 2023
via PubMed
~4 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Development
- Mechanism of action
- Clinical trials
- Preclinical investigations
- See also
- References
- External links
Vorinostat (rINN), also known as suberoylanilide hydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA), is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities.
Vorinostat is marketed under the name Zolinza ( ) by Merck for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after two systemic therapies. The compound was developed by Columbia University chemist Ronald Breslow and Memorial Sloan-Kettering researcher Paul Marks.
Excerpted from Wikipedia’s “vorinostat” article, available under the CC BY-SA 4.0 licence.